Israel is partnering with U.S.-based NRx Pharmaceuticals to complete trials and commercialize the Israeli-developed Covid-19 vaccine BriLife.
Israel reported on July 5 a decrease in the effectiveness of the Pfizer/BioNTech Covid-19 vaccine in preventing infections and symptomatic illness, but said it remained highly effective in preventing serious illness.
The Pfizer-BioNTech vaccine is highly effective against the Delta variant of Covid-19, a Pfizer official in Israel said on June 24.
Preliminary findings from two vaccine safety monitoring systems suggest a higher-than-expected number of cases of heart inflammation after the second dose of mRNA Covid-19 vaccines in young men, the U.S. Centers for Disease Control and Prevention (CDC) said on June 10.
Israel’s Health Ministry found the small number of heart inflammation cases observed mainly in young men who received Pfizer’s Covid-19 vaccine in Israel were likely linked to the company’s vaccination.
The Covid-19 vaccine developed by Pfizer and BioNTech is effective at preventing symptomatic and severe disease in people with some chronic illnesses, like diabetes and heart disease, the biggest real-world study showed on April 22.
Pregnant women vaccinated against Covid-19 could pass along protection to their babies, according to a new study in Israel.
Pfizer Inc. and BioNTech SE said on March 10 that real-world data from Israel suggests their Covid-19 vaccine is 94 percent effective in preventing asymptomatic infections, meaning it could significantly reduce transmission.
Confidence in Covid-19 vaccines is growing, with people’s willingness to have the shots increasing as they are rolled out across the world and concerns about possible side effects are fading, a 14-country survey showed on March 5.
The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.